Biodefense Market to reach $29.6 billion by 2035

Biodefense market was valued at $16.2 billion in 2025 and is projected to reach $29.6 billion by 2035, growing at a CAGR of 6.3% during the forecast period (2026-2035). A primary factor underpinning revenue generation in the biodefense market is the continued allocation of government budgets toward preparedness, countermeasure procurement, and strategic stockpiling. Public sector agencies remain the dominant buyers, directly influencing market size through long-term contracts and centralized purchasing frameworks. According to official budget disclosures, the U.S. government alone proposed approximately $27.0 billion in biodefense spending for FY2026, covering activities across health, defense, and agricultural agencies. Within this allocation, the Department of Health and Human Services accounted for nearly $19.4 billion, reflecting a strong emphasis on medical countermeasures, diagnostics, and stockpile management. In addition, targeted programs such as the Strategic National Stockpile and Project BioShield continue to receive dedicated funding, including $850 million for BioShield and $1 billion for stockpile maintenance. These structured procurement mechanisms translate directly into product-level revenues for manufacturers supplying vaccines, therapeutics, and detection systems. The predictable nature of these funding cycles supports long-term production planning and reinforces stable demand across key segments.

Browse the full report description of “Biodefense Market Size, Share & Trends Analysis Report by Product Type (Detection Systems, Medical Countermeasures, Decontamination Systems, Personal Protective Equipment, and Surveillance & Monitoring Systems), by Technology (Molecular Detection Technologies (PCR, NGS), Immunological Detection Technologies, Nanotechnology-based Detection, and Synthetic Biology), by End User (Military & Defense Agencies, Civil Government & Public Health Agencies, Hospitals & Healthcare Facilities, and Research Institutes & Laboratories), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/biodefense-market

Government-led investment initiatives also extend beyond procurement into research, development, and manufacturing scale-up, further strengthening the commercial pipeline. For instance, federal proposals include $20 billion in mandatory funding over multiple years to enhance biodefense capabilities across agencies such as CDC, NIH, and ASPR. A significant portion of this funding is directed toward the development and acquisition of medical countermeasures, which recorded over $12.6 billion in allocation within biodefense budgets. These investments support the commercialization of next-generation vaccines, biologics, and rapid diagnostic platforms, ensuring a continuous transition from research to revenue-generating products. Moreover, the integration of domestic manufacturing incentives and supply chain resilience programs is encouraging localized production, thereby improving availability and reducing dependency on external suppliers. Such policy-driven demand, combined with structured purchasing frameworks, forms the core economic foundation of the biodefense market and remains critical for accurate market size estimation.

Innovation Leaders Transforming the Biodefense Market

The key players in the biodefense market include Emergent BioSolutions Inc., Bavarian Nordic A/S, Thermo Fisher Scientific Inc., Pfizer Inc., GlaxoSmithKline plc, among others. These companies are advancing innovation in biodefense solutions through the development of high-precision detection technologies, next-generation vaccines and therapeutics, and integrated decontamination and protection systems, enabling rapid identification and effective response to biological threats while supporting national security frameworks and public health preparedness initiatives across critical infrastructure environments.

• In April 2026, the US government awarded Shionogi Inc. a contract worth up to $482 million to expand domestic manufacturing of Fetroja (cefiderocol) and advance the antibiotic as a medical countermeasure against biological threats.

• In April 2026, Lunai Bioworks, Inc. announced that its subsidiary, BioSymetrics, has entered into a revenue-generating, commercial defense-focused collaboration with a specialized biotechnology partner to support the development of an advanced AI-enabled platform for chemical threat assessment, with initial engagement underway and additional engagements currently under discussion.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Product Type
  • By Technology
  • By End User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Emergent BioSolutions Inc., Bavarian Nordic A/S, Thermo Fisher Scientific Inc., Pfizer Inc., GlaxoSmithKline plc, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Biodefense Market Report Segment

By Product Type

• Detection Systems
• Medical Countermeasures
• Decontamination Systems
• Personal Protective Equipment
• Surveillance & Monitoring Systems

By Technology

• Molecular Detection Technologies (PCR, NGS)
• Immunological Detection Technologies
• Nanotechnology-based Detection
• Synthetic Biology

By End User

• Military & Defense Agencies
• Civil Government & Public Health Agencies
• Hospitals & Healthcare Facilities
• Research Institutes & Laboratories

Global Biodefense Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/biodefense-market